Pre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapy
Asian Pacific Journal of Cancer Prevention, cilt.10, sa.6, ss.1151-1158, 2009 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 10 Sayı: 6
- Basım Tarihi: 2009
- Dergi Adı: Asian Pacific Journal of Cancer Prevention
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1151-1158
- Anahtar Kelimeler: Anemia, Bladder cancer, Chemotherapy/radiotherapy, Prognostic factor, Turkey
- Trakya Üniversitesi Adresli: Evet
Özet
Purpose: To evaluate prognostic factors affecting local control (LC), distant metastases-free survival (DMFS) and overall survival (OS) in bladder carcinoma patients undergoing extravesical extension. Patients and Methods: We retrospectively reviewed the charts of 61 consecutive patients with T3 or T4 bladder carcinoma, treated with definitive radiotherapy from 1999 through 2007. Results: Median age was 69 years and follow-up was 29 months. The LC rate was 33% at 4 years and was increased in patients with a Hbε12 g/dl (p=0.003) or a LDH<180 U/L (p=0.021) and in those who received concurrent chemotherapy (p=0.022) on univariate analysis. DMFS was affected by anemia (Hb<12 g/dl) (p=0.039), the absence of chemotherapy (p=0.034) and the presence of newlydiagnosed disease (p=0.01). The OS rate was 19% at 4 years. Non-pure transitional cell carcinoma histological type (p=0.024), anemia (p=0.004), elevated LDH (p=0.003), and newly diagnosed disease (p=0.011) were poor prognostic factors on univariate analyses for OS. Anemia was the only negative prognostic factor for LC (p=0.03), DMFS (p=0.002) and OS (p<0.0001) on multivariate analysis. Conclusion: Pre-treatment Hb level is the most important prognostic factor in patients treated with definitive radiotherapy, so that anemia may act as a surrogate biological marker for aggressive disease.